Overview
ALKS market data
Price History
ALKS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ALKS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Stifel Reiterates Buy on Alkermes, Raises Price Target to $63Benzinga · Jul 20, 2026, 2:44 PM
Needham Maintains Buy on Alkermes, Raises Price Target to $62Benzinga · Jul 13, 2026, 3:48 PM
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy StudyBenzinga · Jul 13, 2026, 3:06 PM
Alkermes Says Interim Analysis From Ogoing Long-term Extension Study Of Alixorexton For Narcolepsy Showed Sustained Clinically Meaningful Improvement In WakefulnessBenzinga · Jul 13, 2026, 11:06 AM
JP Morgan Reinstates Neutral on Alkermes, Announces $60 Price TargetBenzinga · Jul 13, 2026, 11:00 AM
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without PenaltiesBenzinga · Jul 8, 2026, 12:15 PM
8-K filing — Alkermes plc. (ALKS)SEC EDGAR · Jul 8, 2026, 12:00 PM
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $65Benzinga · Jul 2, 2026, 11:35 AM
Wells Fargo Maintains Overweight on Alkermes, Raises Price Target to $65Benzinga · Jun 29, 2026, 1:40 PM
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For MondayBenzinga · Jun 29, 2026, 12:50 PM